Emcure Pharmaceuticals Ltd Analyst Rating
based on 3 analysts
66.67%
Buy
33.33%
Hold
0.00%
Sell
Based on 3 analysts offering long term price targets for Emcure Pharmaceuticals Ltd. An average target of ₹1575
Source: S&P Global Market Intelligence
Emcure Pharmaceuticals Ltd Share analysis
Emcure Pharmaceuticals Ltd price forecast by 3 analysts
Upside of5.45%
High
₹1655
Target
₹1575.00
Low
₹1470
Emcure Pharmaceuticals Ltd target price ₹1575, a slight upside of 5.45% compared to current price of ₹1453.15. According to 3 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Emcure Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2026:0
Forecast
Actual
Including amortisation and stock based compensations
Emcure Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2026:0
Forecast
Actual
Source: S&P Global Market Intelligence
Emcure Pharmaceuticals Ltd Performance
Day's Low
Day's High
₹1,435.05₹1,495.252 Week's Low
52 Week's High
₹1,225₹1,580
| Returns % | |
| 1 Month Return | + 3.41 % |
| 3 Month Return | + 12.86 % |
| 1 Year Return | + 9.9 % |
| Market Stats | |
| Previous Close | ₹1,493.65 |
| Open | ₹1,485.15 |
| Volume | 77.85K |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹28,244.67Cr |
Emcure Pharmaceuticals Ltd Key Statistics
| P/E Ratio | 0 |
| PEG Ratio | 0 |
| Market Cap | ₹28,244.67 Cr |
| P/B Ratio | 0 |
| EPS | 0 |
| Dividend Yield | 0 |
| Sector | Pharmaceuticals |
| ROE | 9.01 |
Emcure Pharmaceuticals Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹28,244.67 Cr | 1.98% | 0.00 | ₹527 Cr | ₹6,658 Cr | |
| NA | ₹207.23 Cr | 49.33% | 0.79 | ₹7 Cr | ₹339 Cr | |
| NA | ₹10.56 Cr | 219.49% | 0.50 | NA | NA | |
| BUY | ₹6,511.04 Cr | 14.02% | 0.62 | ₹48 Cr | ₹717 Cr | |
| NA | ₹28.64 Cr | 67.38% | 0.50 | NA | NA |
Emcure Pharmaceuticals Ltd Mutual Fund Holdings
About Emcure Pharmaceuticals Ltd
Share Price: ₹1453.15 per share as on 21 Oct, 2024 04:01 PM
Market Capitalisation: ₹28,244.67Cr as of today
Revenue: ₹1,815.14Cr as on June 2024 (Q2 24)
Net Profit: ₹152.59Cr as on June 2024 (Q2 24)
Listing date: 10 Jul, 2024
| Organisation | Emcure Pharmaceuticals Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Receives Positive Brokerage Outlook - 07 Oct, 2024
Yes Securities has issued a buy call on Emcure Pharmaceuticals with a target price of ₹1,900, citing strong growth, robust margins, and increased field force. The company ranks 15th in domestic sales and leads in the gynaecology sector, with greater earnings visibility due to limited U.S. generics exposure.
Kotak Initiates Coverage on Emcure Pharmaceuticals - 19 Sep, 2024
Kotak Institutional Equities has initiated coverage on Emcure Pharmaceuticals with a target price of Rs 1,655, citing healthy growth prospects and potential risks from legal challenges and market performance.
Kotak Initiates Coverage on Emcure Pharma Stock - 18 Sep, 2024
Emcure Pharmaceuticals shares surged over 5% after Kotak Institutional Equities initiated coverage with an 'Add' rating and a target price of ₹1,655, indicating an 11% upside potential. The firm highlights Emcure's earnings stability due to no direct US generics exposure and expects strong sales growth over the next few years.
Insights on Emcure Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 7 days, EMCURE stock has moved up by 0.7%
NO EFFECTFII Holding Unchanged
Foreign Institutions holdings remained unchanged at 1.76% of holdings in Jul 2024 quarter
- NO EFFECT
Retail Holding Unchanged
Retail Investor holdings remained unchanged at 16.82% of holdings in Jul 2024 quarter
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 78.08% of holdings in Jul 2024 quarter
Emcure Pharmaceuticals Ltd Financials
Index Inclusions
Emcure Pharmaceuticals Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 78.08% | 0.00 | |
| Foreign Institutions | 1.76% | 0.00 | |
| Mutual Funds | 1.77% | 0.00 | |
| Retail Investors | 16.82% | 0.00 | |
| Others | 1.57% | 0.00 |
Emcure Pharmaceuticals Ltd Key Indicators
Emcure Pharmaceuticals Ltd Earnings and Dividends
Emcure Pharmaceuticals Ltd Earnings Results
Emcure Pharmaceuticals Ltd’s net profit jumped 10.48% since last year same period to ₹144.08Cr in the Q1 2024-2025. On a quarterly growth basis, Emcure Pharmaceuticals Ltd has generated 25.1% jump in its net profits since last 3-months.
Read More about Earnings Results
Emcure Pharmaceuticals Ltd Technicals Summary
Bearish
Neutral
Bullish
Emcure Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Emcure Pharmaceuticals Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Emcure Pharmaceuticals Ltd shares.
Emcure Pharmaceuticals Ltd (EMCURE) share price today is ₹1453.15
Emcure Pharmaceuticals Ltd is listed on NSE
Emcure Pharmaceuticals Ltd is listed on BSE
- Today’s highest price of Emcure Pharmaceuticals Ltd is ₹1495.2.
- Today’s lowest price of Emcure Pharmaceuticals Ltd is ₹1435.05.
Today’s traded volume of Emcure Pharmaceuticals Ltd(EMCURE) is 77.85K.
Today’s market capitalisation of Emcure Pharmaceuticals Ltd(EMCURE) is ₹28244.67Cr.
| Emcure Pharmaceuticals Ltd(EMCURE | Price |
|---|---|
52 Week High | ₹1580 |
52 Week Low | ₹1225 |
Emcure Pharmaceuticals Ltd(EMCURE) share price is ₹1453.15. It is down -8.03% from its 52 Week High price of ₹1580
Emcure Pharmaceuticals Ltd(EMCURE) share price is ₹1453.15. It is up 18.62% from its 52 Week Low price of ₹1225
| Emcure Pharmaceuticals Ltd(EMCURE | Returns |
|---|---|
1 Day Returns | -40.5% |
1 Month Returns | 3.41% |
3 Month Returns | 12.86% |
1 Year Returns | 9.9% |